© 2005 Oxford University Press
ARTICLE |
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Affiliation of authors: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN (YJ, ZD, BW, HH, KHL, TS, AMS, LL, AN, DAF); Breast Cancer Program, University of Michigan, Ann Arbor, MI (LU, JMR, JH, JMR, DFH); Department of Pharmacology, Mayo Clinic, Rochester, MN (AA, RMW); Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (VS);Fox Chase Cancer Center, Philadelphia, PA (RB)
Correspondence to: David A. Flockhart, MD, PhD, Division of Clinical Pharmacology, Indiana University, School of Medicine, 1001 W. 10th St., W. D. Myers Building, W7123, Indianapolis, IN 46202 (e-mail: dflockha{at}iupui.edu)
Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen are associated with the cytochrome P450 (CYP) 2D6 genotype. We examined the effects of concomitant use of selective serotonin reuptake inhibitor antidepressants, which are CYP2D6 enzyme inhibitors commonly prescribed to treat hot flashes in women who take tamoxifen, and genotypes for genes that encode tamoxifen-metabolizing enzymes on plasma concentrations of tamoxifen and its metabolites. Methods: Eighty patients with newly diagnosed with breast cancer who were beginning tamoxifen therapy (20 mg/day orally), 24 of whom were taking CYP2D6 inhibitors, were genotyped for common alleles of the CYP2D6, CYP2C9, CYP3A5, and sulfotransferase (SULT) 1A1 genes. Plasma concentrations of tamoxifen and its metabolites were measured after 1 and 4 months of tamoxifen therapy. Differences in plasma concentrations of tamoxifen and its metabolites between genotype groups were analyzed by the Wilcoxon rank sum test. All statistical tests were two-sided. Results: Among all women, plasma endoxifen concentrations after 4 months of tamoxifen therapy were statistically significantly lower in subjects with a CYP2D6 homozygous variant genotype (20.0 nM, 95% confidence interval [CI] = 11.1 to 28.9 nM) or a heterozygous genotype (43.1 nM, 95% CI = 33.3 to 52.9 nM) than in those with a homozygous wild-type genotype (78.0 nM, 95%CI = 65.9 to 90.1 nM) (both P = .003). Among subjects who carried a homozygous wild-type genotype, the mean plasma endoxifen concentration for those who were using CYP2D6 inhibitors was 58% lower than that for those who were not (38.6 nM versus 91.4 nM, difference = –52.8 nM, 95% CI = –86.1 to –19.5 nM, P = .0025). The plasma endoxifen concentration was slightly reduced in women taking venlafaxine, a weak inhibitor of CYP2D6, whereas the plasma endoxifen concentration was reduced substantially in subjects who took paroxetine (a potent inhibitor of CYP2D6). Genetic variations of CYP2C9, CYP3A5, or SULT1A1 had no statistically significant associations with plasma concentrations of tamoxifen or its metabolites. Conclusion: Interactions between CYP2D6 polymorphisms and coadministered antidepressants and other drugs that are CYP2D6 inhibitors may be associated with altered tamoxifen activity.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Genetic Polymorphisms, Antidepressant Use May Be Associated With Altered Tamoxifen Activity
- Sarah L. Zielinski
J Natl Cancer Inst 2005 97: 1.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  T. Toyama, H. Yamashita, H. Sugiura, N. Kondo, H. Iwase, and Y. Fujii No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 651 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Brauch, T. E. Murdter, M. Eichelbaum, and M. Schwab Pharmacogenomics of Tamoxifen Therapy Clin. Chem., October 1, 2009; 55(10): 1770 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L.H. Snozek, D. J. O'Kane, and A. Algeciras-Schimnich Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2009; 11(5): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shin, S. R. Kayser, and T. Y. Langaee Pharmacogenetics: from discovery to patient care Am. J. Health Syst. Pharm., April 1, 2009; 66(7): 625 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, J. R. Hawse, M. Subramaniam, M. P. Goetz, J. N. Ingle, and T. C. Spelsberg The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor {alpha} for Degradation in Breast Cancer Cells Cancer Res., March 1, 2009; 69(5): 1722 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Breast Cancer Follow-Up: Extending the Focus Beyond Survival Journal Watch Women's Health, February 26, 2009; 2009(226): 1 - 1. [Full Text]
|
|
|
|
|
|
V. C. Jordan A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention Cancer Res., February 15, 2009; 69(4): 1243 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Huang and M. J. Ratain Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J Clin, January 1, 2009; 59(1): 42 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. O. Dezentje, H.-J. Guchelaar, J. W.R. Nortier, C. J.H. van de Velde, and H. Gelderblom Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer Clin. Cancer Res., January 1, 2009; 15(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lustberg and C. L. Shapiro Physical Challenges of Adult Cancer Survivors ASCO Educational Book, January 1, 2009; 2009(1): 564 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jin, D. F. Hayes, L. Li, J. D. Robarge, T. C. Skaar, S. Philips, A. Nguyen, A. Schott, J. Hayden, S. Lemler, et al. Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy J. Clin. Oncol., December 20, 2008; 26(36): 5849 - 5854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Crandall Gene Testing to Predict Tamoxifen-Induced Hot Flashes: New Biological Insights J. Clin. Oncol., December 20, 2008; 26(36): 5841 - 5842. [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong Pharmacogenetics in Breast Cancer Therapy Clin. Cancer Res., December 15, 2008; 14(24): 8027 - 8041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Martin and J. E. Manson Approach to the Patient with Menopausal Symptoms J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4567 - 4575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Patroneva, S. M. Connolly, P. Fatato, R. Pedersen, Q. Jiang, J. Paul, C. Guico-Pabia, J. A. Isler, M. E. Burczynski, and A. I. Nichols An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects Drug Metab. Dispos., December 1, 2008; 36(12): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, et al. Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 J. Clin. Oncol., October 1, 2008; 26(28): 4672 - 4678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Henry, V. Stearns, D. A. Flockhart, D. F. Hayes, and M. Riba Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression Am J Psychiatry, October 1, 2008; 165(10): 1251 - 1255. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., October 1, 2008; 19(10): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goetz, V. J. Suman, F. J. Couch, M. M. Ames, J. M. Rae, M. G. Erlander, X.-J. Ma, D. C. Sgroi, C. A. Reynolds, W. L. Lingle, et al. Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance Clin. Cancer Res., September 15, 2008; 14(18): 5864 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Newman, K. D. Hadfield, A. Latif, S. A. Roberts, A. Shenton, C. McHague, F. Lalloo, S. Howell, and D. G. Evans Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients Clin. Cancer Res., September 15, 2008; 14(18): 5913 - 5918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Leeder, R. E. Pearce, A. Gaedigk, A. Modak, and D. I. Rosen Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype J. Clin. Pharmacol., September 1, 2008; 48(9): 1041 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, Y. Sun, L. Yao, L. Shi, Y. Wu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann. Onc., August 1, 2008; 19(8): 1423 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. McCarty, J. K. Burmester, B. N. Mukesh, R. B. Patchett, and R. A. Wilke Intraocular Pressure Response to Topical {beta}-Blockers Associated With an ADRB2 Single-Nucleotide Polymorphism Arch Ophthalmol, July 1, 2008; 126(7): 959 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Hayes, V. Stearns, J. Rae, D. Flockhart, and on behalf of the Consortium on Breast Cancer Pharm A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients? J Natl Cancer Inst, May 7, 2008; 100(9): 610 - 613. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gjerde, M. Hauglid, H. Breilid, S. Lundgren, J. E. Varhaug, E. R. Kisanga, G. Mellgren, V. M. Steen, and E. A. Lien Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism Ann. Onc., January 1, 2008; 19(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Pritchard Adjuvant Endocrine Therapy of the Future: Potential and Possibilities ASCO Educational Book, January 1, 2008; 2008(1): 18 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Desta and D. A. Flockhart Germline Pharmacogenetics of Tamoxifen Response: Have We Learned Enough? J. Clin. Oncol., November 20, 2007; 25(33): 5147 - 5149. [Full Text] [PDF]
|
|
|
|
|
|
W. Schroth, L. Antoniadou, P. Fritz, M. Schwab, T. Muerdter, U. M. Zanger, W. Simon, M. Eichelbaum, and H. Brauch Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes J. Clin. Oncol., November 20, 2007; 25(33): 5187 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, D. Sun, A. K. Sharma, G. Chen, S. Amin, and P. Lazarus Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation Drug Metab. Dispos., October 1, 2007; 35(10): 1942 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pruthi, J. C. Boughey, K. R. Brandt, A. C. Degnim, G. K. Dy, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, and J. N. Ingle A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations Mayo Clin. Proc., September 1, 2007; 82(9): 1131 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Wu, M. C. Pike, L. D. Williams, D. Spicer, C.-C. Tseng, M. I. Churchwell, and D. R. Doerge Tamoxifen, Soy, and Lifestyle Factors in Asian American Women With Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3024 - 3030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Hayes Follow-up of Patients with Early Breast Cancer N. Engl. J. Med., June 14, 2007; 356(24): 2505 - 2513. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Grabinski Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice Journal of Pharmacy Practice, June 1, 2007; 20(3): 246 - 251. [Abstract] [PDF]
|
|
|
|
|
|
S Loibl, K Schwedler, G von Minckwitz, R Strohmeier, K. Mehta, and M Kaufmann Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study Ann. Onc., April 1, 2007; 18(4): 689 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Carpenter, A. M. Storniolo, S. Johns, P. O. Monahan, F. Azzouz, J. L. Elam, C. S. Johnson, and R. C. Shelton Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer Oncologist, January 1, 2007; 12(1): 124 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grady Management of Menopausal Symptoms N. Engl. J. Med., November 30, 2006; 355(22): 2338 - 2347. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Van Poznak and D. F. Hayes Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? J Natl Cancer Inst, September 20, 2006; 98(18): 1261 - 1263. [Full Text] [PDF]
|
|
|
|
|
|
I. Sestak, R. Kealy, R. Edwards, J. Forbes, and J. Cuzick Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms J. Clin. Oncol., August 20, 2006; 24(24): 3991 - 3996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goetz, J. M. Rae, S. L. Safgren, M. M. Ames, D. W. Visscher, C. Reynolds, F. Couch, W. L. Lingle, D. A. Flockhart, Z. Desta, et al. In Reply J. Clin. Oncol., August 1, 2006; 24(22): 3709 - 3709. [Full Text] [PDF]
|
|
|
|
|
|
J. Yu, M. J. I. Paine, J.-D. Marechal, C. A. Kemp, C. J. Ward, S. Brown, M. J. Sutcliffe, G. C. K. Roberts, E. M. Rankin, and C. R. Wolf IN SILICO PREDICTION OF DRUG BINDING TO CYP2D6: IDENTIFICATION OF A NEW METABOLITE OF METOCLOPRAMIDE Drug Metab. Dispos., August 1, 2006; 34(8): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Lim, L. Li, Z. Desta, Q. Zhao, J. M. Rae, D. A. Flockhart, and T. C. Skaar Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens Symptoms and treatment in cancer therapy-induced early menopause. Oncologist, June 1, 2006; 11(6): 641 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Castro Pharmacogenomics in the Clinic: New Questions About Tamoxifen J. Oncol. Pract, March 1, 2006; 2(2): 100 - 100. [Full Text] [PDF]
|
|
|
|
|
|
S. Bernard, K. A. Neville, A. T. Nguyen, and D. A. Flockhart Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications. Oncologist, February 1, 2006; 11(2): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goetz, J. M. Rae, V. J. Suman, S. L. Safgren, M. M. Ames, D. W. Visscher, C. Reynolds, F. J. Couch, W. L. Lingle, D. A. Flockhart, et al. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes J. Clin. Oncol., December 20, 2005; 23(36): 9312 - 9318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Holmes and J. D. Liticker Pharmacogenomics of Tamoxifen in a Nutshell--And Who Broke the Nutcracker? J. Oncol. Pract, November 1, 2005; 1(4): 155 - 159. [Full Text] [PDF]
|
|
|
|
|
|
V. Stearns, R. Slack, N. Greep, R. Henry-Tilman, M. Osborne, C. Bunnell, L. Ullmer, A. Gallagher, J. Cullen, E. Gehan, et al. Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial J. Clin. Oncol., October 1, 2005; 23(28): 6919 - 6930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ingelman-Sundberg and C. Rodriguez-Antona Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy Phil Trans R Soc B, August 29, 2005; 360(1460): 1563 - 1570. [Abstract] [Full Text] [PDF]
|
|